Colon Cancer

Cancer Type

Blood

Specimen Requirements

10 Working Days

Turnaround Time ¹

ACTMonitor® Colon analyzes 13 forms of circulating tumor DNA in the bloodstream to provide real-time monitoring of drug resistance, early detection of cancer recurrence, and evaluation of treatment response.

Real-Time Monitoring Of Tumor Dynamics

13

Monitoring Genes

1

Report, All Historical Results Consolidated

Hallmarks

Liquid Biopsy Advantages

  • A non-invasive test, which decreases the risk of infection and enables repeated testing at different time points
  • Variants detected can reflect tumor heterogeneity
  • Highly sensitive and real-time monitoring of tumor dynamics
  • Assessment of treatment response, understanding resistance mechanisms and monitoring cancer recurrence

ACTMonitor® Colon Advantages

  • Repeated analyses of liquid biopsies over time enable long-term disease monitoring
  • Provides real-time and comprehensive tumor mutation analyses
  • Monitors treatment outcomes and provides information on the occurrence of mutations that lead to drug resistance
  • Applicable for different types of solid tumors
  • Short turnaround time: 10 working days (starting from the date of receipt of approved samples at our CAP-accredited laboratory)

Summary

Liquid Biopsy to Monitor Tumor Burden and Drug Resistance

ACTMonitor® Colon uses circulating tumor DNA (ctDNA) to provide an early detection of cancer recurrence and drug resistance. ctDNA consists of fragments of DNA released from necrotic or apoptotic tumor cells into the blood stream. ctDNA carries important genetic information of the cancer patient, and changes dramatically before changes can be observed by protein markers or in radio images. Therefore, ctDNA provides a strong basis for molecular diagnostic tests. Monitoring ctDNA can detect the occurrence of variants that would lead to drug sensitivity or resistance, which provides assessment on treatment responses and early detection for cancer recurrence.

Reporting

  • Genetic alteration
  • Drug sensitivity/ resistance information for targeted therapy

Who is Suitable?

  1. Patients with solid tumor unsuitable for surgery
  2. Patients with solid tumor and who have developed drug resistance
  3. Patients with solid tumor and at risk of cancer-recurrence resistance
  4. Patients with solid tumor and who wish to monitor treatment response

Technical Specifications

Next Generation Sequencing (NGS)

13 colon-cancer-related genes

Specimen Requirements2

4-8 mL whole blood x 2 tubes

Sensitivity

y‍0.5% Variant Frequency

Sequencing Mean Depth

7000 X

Documentation

Brochure
Download
Brochure
Download
Brochure
Download
Brochure
Download
Brochure
Download
Brochure
Download
Brochure
Download
Brochure
Download
Brochure
Download
Brochure
Download
Brochure
Download

Disclaimers / Footnotes

  1. Turnaround time starts from the date of receipt of approved samples at our CAP-accredited laboratory.
  2. Please refer to our specimen instructions.
  3. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm504488.htm
  4. https://molecular.roche.com/news/fda-grants-roche-label-extension-for-the-cobas-egfr-mutation-test-v2-for-use-with-plasma-as-a-companion-diagnostic-for-tagrisso/
  5. Fribbens C, et al., J Clin Oncol. 2016 Sep 1;34(25):2961-8
  6. Chandarlapaty S, et al., JAMA Oncol. 2016 Oct 1;2(10):1310-1315

Book a Test

Explore the immense possibilities and promising future of precision medicine. Together, let us unlock the power of genomic testing and personalize cancer care for the most effective treatment.

Get Started